The 1989 Nobel prize winner in Chemistry, Prof. Thomas R. Cech from the University of Colorado BioFrontiers Institute, USA has published a research paper in the 13 December 2012 Nature (492(7428):285-9; I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.” This study provides mechanistic insights into how TPP1 regulates telomerase function.
In connection with this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Anti-cancer stem cell therapeutics: NR2F2 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target genes. Remarkably, over 90% human tumors over express telomerase, suggesting that inhibition of its activity may increase the efficacy of anticancer therapy. Moreover, NR2F2 has been shown to inhibit the expression of stem cell and reprogramming protein Oct-4, suggesting that increased expression of this protein may inhibit the proliferation of cancer stem cells. Together, this study suggests that pharmacological formulations encompassing “NR2F2 or its activators” may be used to inhibit the proliferation of cancer stem cells.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Anti-cancer stem cell therapeutics: NR2F2 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target genes, 05/October/2014, 06.11 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation